How to Read Your Bone Health Markers: What the Hormone Zoomer Reveals About Resorption & Rebuilding

A bone density scan — the DXA — tells you one thing: how much mineral is currently in your bones compared to a reference population. It is a snapshot of where you are. What it cannot tell you is why your bone density is where it is, how fast it is changing, or what is driving the change. For that, you need a different kind of measurement — one that looks at the biological processes of bone remodeling as they are happening in real time.

Bone turnover markers are exactly that: biochemical indicators of osteoclast and osteoblast activity that can be measured in blood or urine and that reflect the current rate of bone resorption and bone formation. They are sensitive enough to detect changes in bone metabolism within weeks — far faster than DXA, which requires 12 to 24 months to show meaningful changes in density. And they provide something that DXA fundamentally cannot: information about the direction and rate of change, and the balance between breakdown and rebuilding.

The Vibrant Wellness Hormone Zoomer includes several of these bone turnover markers alongside the full hormonal panel — making it one of the most comprehensive tools available for understanding bone health from a root-cause perspective. Understanding what these markers mean, what drives them out of range, and how to interpret them in the context of the broader hormonal picture is the subject of this article.

The Two Sides of Bone Remodeling: Resorption and Formation

Bone remodeling is a continuous, lifelong process that occurs in discrete cycles throughout the skeleton. At any given time, approximately 10 percent of the skeleton is undergoing active remodeling. The process has two phases: resorption (breakdown) and formation (rebuilding), and the balance between them determines whether bone density is increasing, stable, or declining.

Bone resorption markers reflect osteoclast activity — the breakdown side of the equation. When osteoclasts dissolve the bone matrix, they release fragments of the collagen that was embedded in it. These fragments — particularly the cross-linking molecules that hold collagen fibers together — are released into the bloodstream and excreted in the urine, where they can be measured as indicators of how much bone is being broken down.

Bone formation markers reflect osteoblast activity — the rebuilding side. When osteoblasts synthesize new bone matrix and mineralize it, they produce and release specific proteins and enzymes that can be measured in the blood as indicators of how actively new bone is being built.

The clinical value of these markers lies not in any single number, but in the relationship between them — and in the context of the hormonal and metabolic environment that is driving them.

Deoxypyridinoline (DPD) and Pyridinoline (PYD): The Collagen Breakdown Markers

Deoxypyridinoline (DPD) and pyridinoline (PYD) are cross-linking amino acids that hold the collagen fibers of bone together. When osteoclasts break down bone matrix, these cross-links are released and excreted in the urine. They are among the most specific markers of bone collagen resorption available — particularly DPD, which is found almost exclusively in bone collagen (PYD is also found in cartilage and other connective tissues).

Elevated DPD and PYD indicate that bone resorption is occurring at an accelerated rate — that osteoclasts are breaking down bone matrix faster than normal. This can occur for many reasons: estrogen deficiency (which removes the primary brake on osteoclast activity), elevated cortisol (which directly stimulates osteoclast activation), chronic inflammation (which drives RANK-L signaling), heavy metal burden (which impairs osteoblast function and creates an imbalance between resorption and formation), and vitamin D deficiency (which increases parathyroid hormone, which stimulates resorption).

The Vibrant Wellness help documentation notes that elevated DPD and PYD can occur even in people without osteoporosis — reflecting accelerated bone turnover that, if sustained, will eventually manifest as measurable bone density loss. This is precisely why these markers are valuable: they can identify a problem years before it shows up on a DXA scan, when there is still ample opportunity to address the root causes and reverse the trajectory.

Osteocalcin: The Bone Formation Marker

Osteocalcin is a protein produced exclusively by osteoblasts — the cells that build new bone. It is the most abundant non-collagen protein in bone, and its primary function is to bind calcium into the hydroxyapatite crystal lattice of the bone matrix. Measuring osteocalcin in the blood provides a direct indicator of osteoblast activity and the rate of new bone formation.

Osteocalcin exists in two forms: carboxylated (active) and undercarboxylated (inactive). The carboxylated form has been activated by vitamin K2 and can bind calcium effectively. The undercarboxylated form cannot. When vitamin K2 is deficient, a higher proportion of osteocalcin remains in its inactive form — which means that even if osteoblasts are producing adequate osteocalcin, the calcium-binding function is impaired. Some advanced panels measure the ratio of carboxylated to undercarboxylated osteocalcin as a direct indicator of vitamin K2 status and bone matrix quality.

Low osteocalcin indicates insufficient osteoblast activity — the formation side of the remodeling equation is underperforming. This can be driven by low IGF-1 (growth hormone deficiency), low testosterone, chronic cortisol elevation, mitochondrial dysfunction in osteoblasts, or heavy metal toxicity that impairs osteoblast function. High osteocalcin, in the context of high resorption markers, indicates a high-turnover state — bone is being broken down and rebuilt rapidly, which can occur in early menopause, hyperparathyroidism, or hyperthyroidism.

Reading the Hormone Zoomer for Bone Health: The Full Picture

The power of the Hormone Zoomer for bone health assessment lies in its ability to provide both the bone turnover markers and the hormonal context that explains them — in a single panel. Here is how to read the key markers together:

High DPD/PYD + Low Estrogen: This pattern is the classic postmenopausal bone loss signature. Estrogen deficiency removes the primary inhibitory signal on osteoclasts, resorption accelerates, and DPD and PYD rise. The priority is addressing the estrogen deficiency — whether through bioidentical hormone support, phytoestrogen-rich nutrition, or addressing the root causes of estrogen deficiency (adrenal dysfunction, liver detoxification impairment, gut dysbiosis affecting estrogen recirculation).

High DPD/PYD + High Cortisol: This pattern indicates stress-driven bone loss. Chronic cortisol elevation directly activates osteoclasts and suppresses osteoblasts. The priority is HPA axis support — addressing the chronic stressors (whether physiological or psychological) that are driving cortisol elevation, and supporting adrenal recovery.

Low Osteocalcin + Low Testosterone: This pattern indicates insufficient bone formation driven by androgen deficiency. Testosterone is a direct anabolic signal for osteoblasts, and its deficiency impairs the formation side of the remodeling equation. This pattern is common in men with andropause and in women with low DHEA.

High DPD/PYD + Low Osteocalcin: This is the most concerning pattern — high resorption combined with low formation. Bone is being broken down faster than it is being rebuilt, and the formation machinery is not compensating. This pattern requires the most comprehensive root-cause investigation: hormonal deficiencies, heavy metal burden, mitochondrial dysfunction, and nutrient co-factor deficiencies all need to be assessed.

High DPD/PYD + Normal or High Osteocalcin: This high-turnover pattern indicates that the body is attempting to compensate for accelerated resorption with increased formation — but the resorption is outpacing the response. This is common in early menopause and in states of chronic inflammation. Reducing the inflammatory and hormonal drivers of resorption is the priority.

What Drives Bone Markers Out of Range: The Root-Cause Checklist

When bone turnover markers are elevated — particularly DPD and PYD — the following root causes should be systematically investigated:

Hormonal deficiencies: Estrogen, progesterone, testosterone, DHEA, and thyroid hormones all regulate bone remodeling. The Hormone Zoomer provides all of these in a single panel, making it possible to identify the specific hormonal drivers of elevated resorption markers.

Vitamin D insufficiency: Low vitamin D increases parathyroid hormone (PTH), which stimulates osteoclast activity and drives resorption. Optimal vitamin D levels (60 to 80 ng/mL) are required to suppress PTH and maintain balanced bone remodeling.

Vitamin K2 deficiency: Indicated by elevated undercarboxylated osteocalcin. Without adequate K2, osteocalcin cannot bind calcium into bone, and the formation process is inefficient even when osteoblast activity is adequate.

Chronic inflammation: Elevated inflammatory markers (hsCRP, IL-6, TNF-alpha) drive RANK-L signaling and osteoclast activation. The source of the inflammation — gut dysbiosis, chronic infections, toxic burden, autoimmunity — must be identified and addressed.

Heavy metal burden: Lead, cadmium, and aluminum all impair osteoblast function and can drive elevated resorption markers. The Total Tox Burden panel from Vibrant Wellness provides a comprehensive assessment of heavy metal, mycotoxin, and environmental chemical burden.

Gut malabsorption: Impaired absorption of calcium, magnesium, vitamin D, and other bone-critical nutrients — driven by gut dysbiosis, low stomach acid, or intestinal permeability — can create functional nutrient deficiencies even with adequate dietary intake.

🌿 Recommended Tools & Resources

These are the specific supplements, protocols, labs, and tools Jacob recommends in connection with the topics covered in this article. All are available through the Beyondetox store or lab portal.

From the Supplement Store

Recommended Protocol

Recommended Functional Lab Testing

References

1. Vasikaran S, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment. Osteoporosis International. 2011;22(2):391-420.
2. Vibrant Wellness. What can cause high bone health markers on the Hormone Zoomer? Vibrant Wellness Help Center. 2025.
3. Woitge HW, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. Journal of Bone and Mineral Research. 1999;14(5):792-801.
4. Guerrero R, et al. New biochemical markers of bone resorption derived from collagen breakdown. Osteoporosis International. 1996;6(1):23-27.
5. Prior JC. Progesterone as a bone-trophic hormone. Endocrine Reviews. 1990;11(2):386-398.
6. Khalil Z, et al. The Medical Benefits of Vitamin K2 on Calcium-Related Disorders. Nutrients. 2021;13(2):691.
7. Rizzoli R, et al. Vitamin D supplementation in elderly or postmenopausal women. Current Medical Research and Opinion. 2013;29(4):305-313.
8. Staessen JA, et al. Environmental exposure to cadmium, forearm bone density, and risk of fractures. The Lancet. 1999;353(9159):1140-1144.
9. Ohlsson C, Sjögren K. Effects of the gut microbiota on bone mass. Trends in Endocrinology & Metabolism. 2015;26(2):69-74.
10. Pizzorno J. The Toxin Solution. HarperOne, 2017.